Early Cancer Interception Shows Promise in Lab and Trials

Research into stopping cancer before it starts shows potential to prevent deaths in high-risk groups, though human applications remain unproven.

Mount Sinai researcher Miriam Merad is studying how inflammation drives early cancer initiation. In one trial, roughly 90 percent of participants with pancreatic abnormalities generated immune cells better at recognizing mutated cells. Canakinumab reduced lung cancer deaths by 67% in a 10,000-person cohort, while the PRECEDE trial monitors 20,000 people with family histories of pancreatic cancer. AI systems also aim to detect microscopic abnormalities in scans. However, cancer interception remains unproven in humans. Mouse studies don’t validate human outcomes, and side effects require precise patient selection to avoid unnecessary exposure. Trial results depend on accurately identifying high-risk individuals. If successful, this approach could prevent cancer deaths by targeting pre-cancerous growths early. For now, it’s experimental work in development across multiple trials and labs.

This research moves health abundance by potentially reducing cancer deaths through early intervention. If validated, it could make cancer prevention more accessible for high-risk populations. But current evidence is limited to lab and trial phases, with significant caveats about human applicability and patient selection.

Source: Singularity Hub